Candidate biochemical markers for screening of pre-eclampsia in early pregnancy

Clinical Chemistry and Laboratory Medicine

Volumn 50, Issue 6, 2012, Pages 973-984

  Forest, Jean Claude ^a,b   Charland, Marc ^a   Massé, Jacques ^b,c   Bujold, Emmanuel ^a,b   Rousseau, François ^a,b   Lafond, Julie ^d   Giguère, Yves ^a,b  

^a LAVAL UNIVERSITY   (Canada)

^b UNIVERSITÉ LAVAL   (Canada)

^c Centre Hospitalier Universitaire (CHU)   (Canada)

^d UNIVERSITÉ DU QUÉBEC À MONTRÉAL   (Canada)

Author keywords

Biochemical markers; Hypertensive disorders of pregnancy; Maternal risk factors; Pre eclampsia; Screening strategies; Ultrasonographic markers

Indexed keywords

ACETYLSALICYLIC ACID; ACTIVIN A; ALPHA FETOPROTEIN; ANGIOGENIC FACTOR; BIOCHEMICAL MARKER; CHORIONIC GONADOTROPIN; INHIBIN A; NUCLEIC ACID; PLACENTA PROTEIN; PLACENTAL GROWTH FACTOR; PREGNANCY ASSOCIATED PLASMA PROTEIN A; VASCULOTROPIN; BIOLOGICAL MARKER;

ALGORITHM; CHROMOSOME ABERRATION; DEPRESSION; DOPPLER ECHOGRAPHY; DOWN SYNDROME; ECHOGRAPHY; ENDOTHELIAL DYSFUNCTION; FEMALE; FERTILIZATION IN VITRO; FETUS HYDROPS; GINGIVITIS; HIGH RISK POPULATION; HUMAN; HYPERCOAGULABILITY; HYPERTENSION; INSULIN RESISTANCE; LOW DRUG DOSE; MARRIAGE; MATERNAL HYPERTENSION; METABOLOMICS; NIDATION; OBESITY; OXIDATIVE STRESS; PREECLAMPSIA; PREGNANCY COMPLICATION; PREGNANCY OUTCOME; PREMATURE LABOR; PRIMIPARA; PRIORITY JOURNAL; PROTEINURIA; PROTEOMICS; REVIEW; RISK FACTOR; SCREENING; SENSITIVITY AND SPECIFICITY; SYSTEMATIC REVIEW (TOPIC); TWIN PREGNANCY; URINARY EXCRETION; UTERINE ARTERY; WORLD HEALTH ORGANIZATION; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PREGNANCY;

BIOLOGICAL MARKERS; EMBRYO IMPLANTATION; FEMALE; HUMANS; PRE-ECLAMPSIA; PREGNANCY; RISK FACTORS;

EID: 84867414988     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/CCLM.2011.820     Document Type: Review

References (137)

1. Brown MA, Lindheimer MD, De Swiet M, Van Assche A, Moutquin JM. The classification and diagnosis of the hypertensive disorders of pregnancy: statement from the International Society for the Study of Hypertension in Pregnancy (ISSHP). Hypertens Pregnancy 2001;20:IX-XIV.
2. Magee L, Helewa M, Moutquin J, Von Dadelszen P. Diagnosis, evaluation and management of the hypertensive disorders of pregnancy. J Obst Gynaecol Can 2008;30:S1-50.
3. Lindheimer MD, Taler SJ, Cunningham FG. ASH position paper: hypertension in pregnancy. J Clin Hypertens (Greenwich) 2009;11:214-25.
4. Sibai B, Dekker G, Kupferminc M. Pre-eclampsia. Lancet 2005;365:785-99.
5. Wallis AB, Saftlas AF, Hsia J, Atrash HK. Secular trends in the rates of preeclampsia, eclampsia, and gestational hypertension, United States, 1987-2004. Am J Hypertens 2008;21:521-6.
6. Walker RL, Hemmelgarn B, Quan H. Incidence of gestational hypertension in the Calgary Health Region from 1995 to 2004. Can J Cardiol 2009;25:e284-7.
7. CEMACH. Why mothers die 2000-2002. In: Lewis G, editor. The sixth report of the confidential enquiries into maternal deaths in the United Kingdom. London: RCOG Press, 2004:340.
8. Moodley J. Maternal deaths due to hypertensive disorders in pregnancy: saving mothers report 2002-2004. Cardiovasc J Afr 2007;18:358-61.
9. Duley L. The global impact of pre-eclampsia and eclampsia. Semin Perinatol 2009;33:130-7.
10. Dekker G, Sibai B. Primary, secondary, and tertiary prevention of pre-eclampsia. Lancet 2001;357:209-15.
11. Goldenberg RL, Culhane JF, Iams JD, Romero R. Epidemiology and causes of preterm birth. Lancet 2008;371:75-84.
12. Barton JR, Istwan NB, Rhea D, Collins A, Stanziano GJ. Cost-savings analysis of an outpatient management program for women with pregnancy-related hypertensive conditions. Dis Manag 2006;9:236-41.
13. Liu A, Wen SW, Bottomley J, Walker MC, Smith G. Utilization of health care services of pregnant women complicated by preec-lampsia in Ontario. Hypertens Pregnancy 2009;28:76-84.
14. Craici I, Wagner S, Garovic VD. Preeclampsia and future cardiovascular risk: formal risk factor or failed stress test ? Ther Adv Cardiovasc Dis 2008;2:249-59.
15. Levesque S, Moutquin JM, Lindsay C, Roy MC, Rousseau F. Implication of an AGT haplotype in a multigene association study with pregnancy hypertension. Hypertension 2004;43:71-8.
16. Bernard N, Girouard J, Forest JC, Giguere Y. The combination of ApoCIII, hepatic lipase and hormono sensitive lipase gene polymorphisms suggests an association with susceptibility to gesta-tional hypertension. J Hum Genet 2007;52:244-54.
17. Sibai BM, Ross MG. Hypertension in gestational diabetes mel-litus: pathophysiology and long-term consequences. J Matern Fetal Neonatal Med 2010;23:229-33.
18. Forest JC, Girouard J, Masse J, Moutquin JM, Kharfi A, Ness RB, et al. Early occurrence of metabolic syndrome after hypertension in pregnancy. Obstet Gynecol 2005;105:1373-80.
19. Bellamy L, Casas JP, Hingorani AD, Williams DJ. Pre-eclampsia and risk of cardiovascular disease and cancer in later life: systematic review and meta-analysis. Br Med J 2007;335:974.
20. McDonald SD, Malinowski A, Zhou Q, Yusuf S, Devereaux PJ. Cardiovascular sequelae of preeclampsia/eclampsia: a systematic review and meta-analyses. Am Heart J 2008;156:918-30.
21. Steegers EA, Von Dadelszen P, Duvekot JJ, Pijnenborg R. Pre-eclampsia. Lancet 2010;376:631-44.
22. Cetin I, Huppertz B, Burton G, Cuckle H, Gonen R, Lapaire O, et al. Pregenesys pre-eclampsia markers consensus meeting: what do we require from markers, risk assessment and model systems to tailor preventive strategies ? Placenta 2011;32(Suppl):S4-16.
23. Bujold E, Morency AM, Roberge S, Lacasse Y, Forest JC, Giguere Y. Acetylsalicylic acid for the prevention of preeclamp-sia and intra-uterine growth restriction in women with abnormal uterine artery Doppler: a systematic review and meta-analysis. J Obstet Gynaecol Can 2009;31:818-26.
24. Bujold E, Roberge S, Lacasse Y, Bureau M, Audibert F, Marcoux S, et al. Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: a meta-analy-sis. Obstet Gynecol 2010;116:402-14.
25. Conde-Agudelo A, Villar J, Lindheimer M. World Health Organization systematic review of screening tests for preeclamp-sia. Obstet Gynecol 2004;104:1367-91.
26. Cnossen JS, Van Der Post JA, Mol BW, Khan KS, Meads CA, Ter Riet G. Prediction of pre-eclampsia: a protocol for systematic reviews of test accuracy. BMC Pregnancy Childbirth 2006;6:29.
27. Wilson J, Jungner G. Principles and practice of screening for disease. Geneva: World Health Organization, 1968.
28. Holland W, Stewart S, Masseria C. Policy brief: screening in Europe. Brussels: World Health Organization on behalf of European Observatory on Health Systems and Policies, 2006.
29. Akolekar R, Syngelaki A, Sarquis R, Zvanca M, Nicolaides KH. Prediction of early, intermediate and late pre-eclampsia from maternal factors, biophysical and biochemical markers at 11-13 weeks. Prenat Diagn 2011;31:66-74.
30. Report of the National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy. Am J Obstet Gynecol 2000;183:S1-22.
31. Sibai BM. Chronic hypertension in pregnancy. Obstet Gynecol 2002;100:369-77.
32. Milne F, Redman C, Walker J, Baker P, Black R, Blincowe J, et al. Assessing the onset of pre-eclampsia in the hospital day unit: summary of the pre-eclampsia guideline (PRECOG II). Br Med J 2009;339:b3129.
33. Dekker GA. Risk factors for preeclampsia. Clin Obstet Gynecol 1999;42:422-35.
34. Duckitt K, Harrington D. Risk factors for pre-eclampsia at antenatal booking: systematic review of controlled studies. Br Med J 2005;330:565.
35. Eskenazi B, Fenster L, Sidney S. A multivariate analysis of risk factors for preeclampsia. J Am Med Assoc 1991;266:237-41.
36. Stone CD, Diallo O, Shyken J, Leet T. The combined effect of maternal smoking and obesity on the risk of preeclampsia. J Perinat Med 2007;35:28-31.
37. Silbergeld EK, Patrick TE. Environmental exposures, toxicologic mechanisms, and adverse pregnancy outcomes. Am J Obstet Gynecol 2005;192:S11-21.
38. Klonoff-Cohen HS, Cross JL, Pieper CF. Job stress and preec-lampsia. Epidemiology 1996;7:245-9.
39. Kurki T, Hiilesmaa V, Raitasalo R, Mattila H, Ylikorkala O. Depression and anxiety in early pregnancy and risk for preec-lampsia. Obstet Gynecol 2000;95:487-90.
40. Qiu C, Sanchez SE, Lam N, Garcia P, Williams MA. Associations of depression and depressive symptoms with preeclampsia: results from a Peruvian case-control study. BMC Womens Health 2007;7:15.
41. Gavard JA, Artal R. Effect of exercise on pregnancy outcome. Clin Obstet Gynecol 2008;51:467-80.
42. Qiu C, Coughlin KB, Frederick IO, Sorensen TK, Williams MA. Dietary fiber intake in early pregnancy and risk of subsequent preeclampsia. Am J Hypertens 2008;21:903-9.
43. Marcoux S, Brisson J, Fabia J. The effect of cigarette smoking on the risk of preeclampsia and gestational hypertension. Am J Epidemiol 1989;130:950-7.
44. Wikstrom AK, Stephansson O, Cnattingius S. Tobacco use during pregnancy and preeclampsia risk: effects of cigarette smoking and snuff. Hypertension 2010;55:1254-9.
45. Silasi M, Cohen B, Karumanchi SA, Rana S. Abnormal placenta-tion, angiogenic factors, and the pathogenesis of preeclampsia. Obstet Gynecol Clin North Am 2010;37:239-53.
46. Williams D. Pregnancy: a stress test for life. Curr Opin Obstet Gynecol 2003;15:465-71.
47. Greer IA. Thrombosis in pregnancy: maternal and fetal issues. Lancet 1999;353:1258-65.
48. Dusse LM, Rios DR, Pinheiro MB, Cooper AJ, Lwaleed BA. Pre-eclampsia: relationship between coagulation, fibrinolysis and inflammation. Clin Chim Acta 2011;412:17-21.
49. Myatt L, Webster RP. Vascular biology of preeclampsia. J Thromb Haemost 2009;7:375-84.
50. Shenoy V, Kanasaki K, Kalluri R. Pre-eclampsia: connecting angiogenic and metabolic pathways. Trends Endocrinol Metab 2010;21:529-36.
51. Page EW. The relation between hydatid moles, relative ischemia of the gravid uterus, and the placental origin of eclampsia. Am J Obstet Gynecol 1939;37:291-3.
52. James JL, Whitley GS, Cartwright JE. Pre-eclampsia: fitting together the placental, immune and cardiovascular pieces. J Pathol 2010;221:363-78.
53. Hellmuth E, Damm P, Molsted-Pedersen L. Oral hypogly-caemic agents in 118 diabetic pregnancies. Diabet Med 2000;17:507-11.
54. Masse J, Forest JC, Moutquin JM, Degrandpre P, Forest VI. A prospective longitudinal study of platelet angiotensin II receptors for the prediction of preeclampsia. Clin Biochem 1998;31:251-5.
55. Young BC, Levine RJ, Karumanchi SA. Pathogenesis of preec-lampsia. Annu Rev Pathol 2010;5:173-92.
56. Forest JC, Masse J, Moutquin JM, Radouco-Thomas M. Preeclampsia: physiopathology and prospects for early detection. Clin Biochem 1989;22:483-9.
57. Gant NF, Daley GL, Chand S, Whalley PJ, MacDonald PC. A study of angiotensin II pressor response throughout primigravid pregnancy. J Clin Invest 1973;52:2682-9.
58. Redman CW, Bodmer JG, Bodmer WF, Beilin LJ, Bonnar J. HLA antigens in severe pre-eclampsia. Lancet 1978;2:397-9.
59. Adam B, Malatyalioglu E, Alvur M, Kokcu A, Bedir A. Plasma atrial natriuretic peptide levels in preeclampsia and eclampsia. J Matern Fetal Invest 1998;8:85-8.
60. Malee MP, Malee KM, Azuma SD, Taylor RN, Roberts JM. Increases in plasma atrial natriuretic peptide concentration antedate clinical evidence of preeclampsia. J Clin Endocrinol Metab 1992;74:1095-100.
61. Roberts JM. Endothelial dysfunction in preeclampsia. Semin Reprod Endocrinol 1998;16:5-15.
62. Vatten LJ, Skjaerven R. Is pre-eclampsia more than one disease? Br J Obstet Gynecol 2004;111:298-302.
63. Cartwright JE, Fraser R, Leslie K, Wallace AE, James JL. Remodelling at the maternal-fetal interface: relevance to human pregnancy disorders. Reproduction 2010;140:803-13.
64. Harris LK. Review: trophoblast-vascular cell interactions in early pregnancy: how to remodel a vessel. Placenta 2010;31(Suppl):S93-8.
65. Staff AC, Dechend R, Pijnenborg R. Learning from the placenta: acute atherosis and vascular remodeling in preeclampsia-novel aspects for atherosclerosis and future cardiovascular health. Hypertension 2010;56:1026-34.
66. Maynard S, Epstein FH, Karumanchi SA. Preeclampsia and angiogenic imbalance. Annu Rev Med 2008;59:61-78.
67. Levine R, Maynard S, Qian C, Lim K-H, England L, Yu K, et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 2004;350:672-83.
68. Thadhani R, Ecker JL, Mutter WP, Wolf M, Smirnakis KV, Sukhatme VP, et al. Insulin resistance and alterations in angiogen-esis: additive insults that may lead to preeclampsia. Hypertension 2004;43:988-92.
69. Widmer M, Villar J, Benigni A, Conde-Agudelo A, Karumanchi SA, Lindheimer M. Mapping the theories of preeclampsia and the role of angiogenic factors: a systematic review. Obstet Gynecol 2007;109:168-80.
70. Venkatesha S, Toporsian M, Lam C, Hanai J, Mammoto T, Kim YM, et al. Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med 2006;12:642-9.
71. Levine RJ, Lam C, Qian C, Yu KF, Maynard SE, Sachs BP, et al. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med 2006;355:992-1005.
72. Myatt L, Kossenjans W, Sahay R, Eis A, Brockman D. Oxidative stress causes vascular dysfunction in the placenta. J Matern Fetal Med 2000;9:79-82.
73. Gupta S, Agarwal A, Sharma RK. The role of placental oxidative stress and lipid peroxidation in preeclampsia. Obstet Gynecol Surv 2005;60:807-16.
74. Leblanc S, Ouellet A, Giguere Y, Forest JC, Moutquin JM, Aris A. A positive correlation between hydrogen peroxide and soluble TNF-alpha receptor 2 early in maternal blood and at term in placenta of pregnant women with preeclampsia. Hypertens Pregnancy. 2010 Dec. 21 [Epub ahead of print].
75. Walsh S. Eicosanoids in preeclampsia. Prostaglandins Leukot Essent Fatty Acids 2004;70:223-32.
76. Parra M, Rodrigo R, Barja P, Bosco C, Fernandez V, Munoz H, et al. Screening test for preeclampsia through assessment of uteroplacental blood flow and biochemical markers of oxida-tive stress and endothelial dysfunction. Am J Obstet Gynecol 2005;193:1486-91.
77. Topal G, Foudi N, Uydes-Dogan BS, Cachina T, Kucur M, Gezer A, et al. Involvement of prostaglandin F2alpha in preeclamptic human umbilical vein vasospasm: a role of prostaglandin F and thromboxane A2 receptors. J Hypertens 2010;28:2438-45.
78. Genc H, Uzun H, Benian A, Simsek G, Gelisgen R, Madazli R, et al. Evaluation of oxidative stress markers in first trimester for assessment of preeclampsia risk. Arch Gynecol Obstet 2011;284:1367-73.
79. Islami D, Shoukir Y, Dupont P, Campana A, Bischof P. Is cellular fibronectin a biological marker for pre-eclampsia ? Eur J Obstet Gynecol Reprod Biol 2001;97:40-5.
80. Wolf M, Kettyle E, Sandler L, Ecker JL, Roberts J, Thadhani R. Obesity and preeclampsia: the potential role of inflammation. Obstet Gynecol 2001;98:757-62.
81. Savvidou M, Lees C, Parra M, Hingorani A, Nocolaides K. Levels of C-reactive protein in pregnant women who subsequently develop pre-eclampsia. Br J Obstet Gynecol 2002;109:297-301.
82. Page N, Kemp C, Butlin D, Lowry P. Placental peptides as markers of gestational disease. Reproduction 2002;123:487-95.
83. Djurovic S, Schjetlein R, Wisløff F, Haugen G, Berg K. Increased levels of intercellular adhesion molecules and vascular cell adhesion molecules in pre-eclampsia. Br J Obstet Gynaecol 1997;104:466-70.
84. Higgins JR, Papayianni A, Brady HR, Darling MR, Walshe JJ. Circulating vascular cell adhesion molecule-1 in pre-ec-lampsia, gestational hypertension, and normal pregnancy: evidence of selective dysregulation of vascular cell adhesion molecule-1 homeostasis in pre-eclampsia. Am J Obstet Gynecol 1998;179:464-9.
85. Szarka A, Rigo J Jr, Lazar L, Beko G, Molvarec A. Circulating cytokines, chemokines and adhesion molecules in normal pregnancy and preeclampsia determined by multiplex suspension array. BMC Immunol 2010;11:59.
86. Lewis DF, Canzoneri BJ, Gu Y, Zhao S, Wang Y. Maternal levels of prostacyclin, thromboxane, ICAM, and VCAM in normal and preeclamptic pregnancies. Am J Reprod Immunol 2010;64:376-83.
87. Akolekar R, Veduta A, Minekawa R, Chelemen T, Nicolaides KH. Maternal plasma P-selectin at 11 to 13 weeks of gestation in hypertensive disorders of pregnancy. Hypertens Pregnancy 2011;30:311-21.
88. Tjoa ML, Oudejans CB, Van Vugt JM, Blankenstein MA, Van Wijk IJ. Markers for presymptomatic prediction of preeclamp-sia and intrauterine growth restriction. Hypertens Pregnancy 2004;23:171-89.
89. Morris RK, Cnossen JS, Langejans M, Robson SC, Kleijnen J, Ter Riet G, et al. Serum screening with Down's syndrome markers to predict pre-eclampsia and small for gestational age: systematic review and meta-analysis. BMC Pregnancy Childbirth 2008;8:33.
90. Wald NJ, Morris JK. Multiple marker second trimester serum screening for pre-eclampsia. J Med Screen 2001;8:65-8.
91. Dugoff L, Hobbins JC, Malone FD, Vidaver J, Sullivan L, Canick JA, et al. Quad screen as a predictor of adverse pregnancy outcome. Obstet Gynecol 2005;106:260-7.
92. Kharfi A, Giguere Y, De Grandpre P, Moutquin JM, Forest JC. Human chorionic gonadotropin (hCG) may be a marker of systemic oxidative stress in normotensive and preeclamptic term pregnancies. Clin Biochem 2005;38:717-21.
93. Spencer K, Cowans NJ, Nicolaides KH. Low levels of maternal serum PAPP-A in the first trimester and the risk of pre-eclamp-sia. Prenat Diagn 2008;28:7-10.
94. Poon LC, Maiz N, Valencia C, Plasencia W, Nicolaides KH. First-trimester maternal serum pregnancy-associated plasma protein-A and pre-eclampsia. Ultrasound Obstet Gynecol 2009;33:23-33.
95. Burger O, Pick E, Zwickel J, Klayman M, Meiri H, Slotky R, et al. Placental protein 13 (PP-13): effects on cultured tropho-blasts, and its detection in human body fluids in normal and pathological pregnancies. Placenta 2004;25:608-22.
96. Nicolaides KH, Bindra R, Turan OM, Chefetz I, Sammar M, Meiri H, et al. A novel approach to first-trimester screening for early pre-eclampsia combining serum PP-13 and Doppler ultrasound. Ultrasound Obstet Gynecol 2006;27:13-7.
97. Spencer K, Cowans NJ, Chefetz I, Tal J, Kuhnreich I, Meiri H. Second-trimester uterine artery Doppler pulsatility index and maternal serum PP13 as markers of pre-eclampsia. Prenat Diagn 2007;27:258-63.
98. Lo YM, Corbetta N, Chamberlain PF, Rai V, Sargent IL, Redman CW, et al. Presence of fetal DNA in maternal plasma and serum. Lancet 1997;350:485-7.
99. Hahn S, Rusterholz C, Hosli I, Lapaire O. Cell-free nucleic acids as potential markers for preeclampsia. Placenta 2011;32(Suppl):S17-20.
100. Chan LY, Leung TN, Chan KC, Tai HL, Lau TK, Wong EM, et al. Serial analysis of fetal DNA concentrations in maternal plasma in late pregnancy. Clin Chem 2003;49:678-80.
101. Chiu RW, Akolekar R, Zheng YW, Leung TY, Sun H, Chan KC, et al. Non-invasive prenatal assessment of trisomy 21 by multiplexed maternal plasma DNA sequencing: large scale validity study. Br Med J 2011;342:c7401.
102. Lo YM, Leung TN, Tein MS, Sargent IL, Zhang J, Lau TK, et al. Quantitative abnormalities of fetal DNA in maternal serum in preeclampsia. Clin Chem 1999;45:184-8.
103. Farina A, Sekizawa A, Iwasaki M, Matsuoka R, Ichizuka K, Okai T. Total cell-free DNA (beta-globin gene) distribution in maternal plasma at the second trimester: a new prospective for preeclampsia screening. Prenat Diagn 2004;24:722-6.
104. Farina A, Sekizawa A, Rizzo N, Concu M, Banzola I, Carinci P, et al. Cell-free fetal DNA (SRY locus) concentration in maternal plasma is directly correlated to the time elapsed from the onset of preeclampsia to the collection of blood. Prenat Diagn 2004;24:293-7.
105. Diesch CH, Holzgreve W, Hahn S, Zhong XY. Comparison of activin A and cell-free fetal DNA levels in maternal plasma from patients at high risk for preeclampsia. Prenat Diagn 2006;26:1267-70.
106. Chim SS, Tong YK, Chiu RW, Lau TK, Leung TN, Chan LY, et al. Detection of the placental epigenetic signature of the maspin gene in maternal plasma. Proc Natl Acad Sci USA 2005;102:14753-8.
107. Tsui DW, Chan KC, Chim SS, Chan LW, Leung TY, Lau TK, et al. Quantitative aberrations of hypermethylated RASSF1A gene sequences in maternal plasma in pre-eclampsia. Prenat Diagn 2007;27:1212-8.
108. Poon LL, Leung TN, Lau TK, Lo YM. Presence of fetal RNA in maternal plasma. Clin Chem 2000;46:1832-4.
109. Purwosunu Y, Sekizawa A, Farina A, Wibowo N, Okazaki S, Nakamura M, et al. Cell-free mRNA concentrations of CRH, PLAC1, and selectin-P are increased in the plasma of pregnant women with preeclampsia. Prenat Diagn 2007;27:772-7.
110. Purwosunu Y, Sekizawa A, Koide K, Farina A, Wibowo N, Wiknjosastro GH, et al. Cell-free mRNA concentrations of plasminogen activator inhibitor-1 and tissue-type plasminogen activator are increased in the plasma of pregnant women with preeclampsia. Clin Chem 2007;53:399-404.
111. Purwosunu Y, Sekizawa A, Okazaki S, Farina A, Wibowo N, Nakamura M, et al. Prediction of preeclampsia by analysis of cell-free messenger RNA in maternal plasma. Am J Obstet Gynecol 2009;200:386 e1-7.
112. Hoffman C, Galan HL. Assessing the at-risk' fetus: Doppler ultrasound. Curr Opin Obstet Gynecol 2009;21:161-6.
113. Irion O, Masse J, Forest JC, Moutquin JM. Prediction of pre-eclampsia, low birthweight for gestation and prematurity by uterine artery blood flow velocity waveforms analysis in low risk nulliparous women. Br J Obstet Gynaecol 1998;105:422-9.
114. Cnossen JS, Morris RK, Ter Riet G, Mol BW, Van Der Post JA, Coomarasamy A, et al. Use of uterine artery Doppler ultra-sonography to predict pre-eclampsia and intrauterine growth restriction: a systematic review and bivariable meta-analysis. Can Med Assoc J 2008;178:701-11.
115. Stampalija T, Gyte GM, Alfirevic Z. Utero-placental Doppler ultrasound for improving pregnancy outcome. Cochrane Database Syst Rev 2010;9:CD008363.
116. Buhimschi IA, Zhao G, Funai EF, Harris N, Sasson IE, Bernstein IM, et al. Proteomic profiling of urine identifies specific fragments of SERPINA1 and albumin as biomarkers of preeclamp-sia. Am J Obstet Gynecol 2008;199:551 e1-16.
117. Carty DM, Siwy J, Brennand JE, Zurbig P, Mullen W, Franke J, et al. Urinary proteomics for prediction of preeclampsia. Hypertension 2011;57:561-9.
118. Kenny LC, Broadhurst DI, Dunn W, Brown M, North RA, McCowan L, et al. Robust early pregnancy prediction of later preeclampsia using metabolomic biomarkers. Hypertension 2010;56:741-9.
119. Odibo AO, Goetzinger KR, Odibo L, Cahill AG, Macones GA, Nelson DM, et al. First-trimester prediction of preeclampsia using metabolomic biomarkers: a discovery phase study. Prenat Diagn 2011;31:990-4.
120. Masse J, Forest JC, Moutquin JM, Marcoux S, Brideau NA, Belanger M. A prospective study of several potential biologic markers for early prediction of the development of preeclamp-sia. Am J Obstet Gynecol 1993;169:501-8.
121. Meads CA, Cnossen JS, Meher S, Juarez-Garcia A, Ter Riet G, Duley L, et al. Methods of prediction and prevention of pre-eclampsia: systematic reviews of accuracy and effectiveness literature with economic modelling. Health Technol Assess 2008;12:iii-iv, 1-270.
122. Cuckle HS. Screening for pre-eclampsia-lessons from aneu-ploidy screening. Placenta 2011;32(Suppl):S42-8.
123. Visintin C, Mugglestone MA, Almerie MQ, Nherera LM, James D, Walkinshaw S. Management of hypertensive disorders during pregnancy: summary of NICE guidance. Br Med J 2010;341:c2207.
124. Poon LC, Kametas NA, Chelemen T, Leal A, Nicolaides KH. Maternal risk factors for hypertensive disorders in pregnancy: a multivariate approach. J Hum Hypertens 2010;24:104-10.
125. North RA, McCowan LM, Dekker GA, Poston L, Chan EH, Stewart AW, et al. Clinical risk prediction for pre-eclampsia in nulliparous women: development of model in international prospective cohort. Br Med J 2011;342:d1875.
126. Nicolaides KH. Turning the pyramid of prenatal care. Fetal Diagn Ther 2011;29:189-96.
127. Giguere Y, Charland M, Bujold E, Bernard N, Grenier S, Rousseau F, et al. Combining biochemical and ultrasonographic markers in predicting preeclampsia: a systematic review. Clin Chem 2010;56:361-75.
128. Akolekar R, Syngelaki A, Beta J, Kocylowski R, Nicolaides KH. Maternal serum placental protein 13 at 11-13 weeks of gestation in preeclampsia. Prenat Diagn 2009;29:1103-8.
129. Deeks JJ, Altman DG. Diagnostic tests 4: likelihood ratios. Br Med J 2004;329:168-9.
130. Spencer K, Cowans NJ, Nicolaides KH. Maternal serum inhibin-A and activin-A levels in the first trimester of pregnancies developing pre-eclampsia. Ultrasound Obstet Gynecol 2008;32:622-6.
131. Spencer K, Yu CK, Cowans NJ, Otigbah C, Nicolaides KH. Prediction of pregnancy complications by first-trimester maternal serum PAPP-A and free beta-hCG and with second-trimester uterine artery Doppler. Prenat Diagn 2005;25:949-53.
132. Spencer K, Cowans NJ, Stamatopoulou A. ADAM12s in maternal serum as a potential marker of pre-eclampsia. Prenat Diagn 2008;28:212-6.
133. Diab AE, El-Behery MM, Ebrahiem MA, Shehata AE. Angiogenic factors for the prediction of pre-eclampsia in women with abnormal midtrimester uterine artery Doppler velocimetry. Int J Gynaecol Obstet 2008;102:146-51.
134. Jauniaux E, Gulbis B, Tunkel S, Ramsay B, Campbell S, Meuris S. Maternal serum testing for alpha-fetoprotein and human cho-rionic gonadotropin in high-risk pregnancies. Prenat Diagn 1996;16:1129-35.
135. Sibai BM. Diagnosis and management of gestational hypertension and preeclampsia. Obstet Gynecol 2003;102:181-92.
136. Thangaratinam S, Langenveld J, Mol BW, Khan KS. Prediction and primary prevention of pre-eclampsia. Best Pract Res Clin Obstet Gynaecol 2011;25:419-33.
137. Thadhani R, Mutter WP, Wolf M, Levine RJ, Taylor RN, Sukhatme VP, et al. First trimester placental growth factor and soluble Fms-like tyrosine kinase 1 and risk for preeclampsia. J Clin Endocrinol Metab 2004;89:770-5.